Factor-H binding protein (fHBP; GNA1870) is one of the antigens of the five-component recombinant vaccine against serogroup B Neisseria meningitidis, which has been developed using 'Reverse Vaccinology' and that is the basis of a meningococcal B vaccine entering phase III clinical trials. Binding of factor H (fH), an inhibitor of the complement alternative pathway, to fHBP enables N. meningitidis to evade killing by the innate immune system. All fHBP null mutant strains analyzed were sensitive to killing in ex vivo human whole blood and serum models of meningococcal bacteremia, with respect to the isogenic wild type strains. The ∆fHBP strains of MC58 and BZ83 (high fHBP expressors) survived in human blood and serum less than 60 minutes (decrease of >2 log 10 CFU), while NZ98/254 (intermediate fHBP expressor) and 67/00 (low fHBP expressor) showed a decrease of >1 log 10 CFU after 60-120 minutes incubation. In addition, fHBP is important for survival in the presence of the antimicrobial peptide LL-37 (decrease of >3 log 10
INTRODUCTION
Disease caused by Neisseria meningitidis remains a major worldwide cause of morbidity and mortality even after the development of vaccines to protect against several meningococcal serogroups. N. meningitidis colonizes the mucosa of the nasopharynx of 5-10% of the population, and in susceptible individuals the bacterium can cross the epithelial layer into the bloodstream, causing septicemia and/or meningitis (36) (10, 33) . The MenB vaccine contains the Genome-derived Neisseria Antigens GNA1870 (fHBP), GNA1994 (NadA), GNA2132, GNA1030 and GNA2091 (10) .
GNA1870 is a 28kDa surface exposed lipoprotein that binds factor H (fH), a key inhibitor of the complement alternative pathway (AP), leading to evasion of killing by the innate immune system. GNA1870 has thus been named factor H binding protein (fHBP) (25) . This antigen is expressed by all N. meningitidis strains studied to date, however the level of expression varies between strains (high, intermediate, or low expressors). fHBP has also been found in the culture supernatant of strain MC58 (26) . fHBP induces high levels of bactericidal antibodies, and even the very low expressors are efficiently killed in serum bactericidal activity (SBA) assays (44) , which are used as the main correlate of protection for meningococcal disease (42) . In addition, anti-fHBP 4 antibodies can block binding of fH, increasing the susceptibility to killing by the complement AP (2, 25) . However, it has recently been suggested that unlike fHBP of high expressors, fHBP of low expressors is not required for survival in nonimmune human blood or in the presence of certain anti-fHBP monoclonal antibodies (mAbs) (43) . Antibodies to fHBP (mAbs (44) and polyclonal antibodies (26) to the recombinant protein, or antibodies elicited by an fHBP enriched OMV vaccine (16) ), also confer passive protection against N. meningitidis bacteremia in an infant rat model. fHBP can be classified into three allelic groups (variant 1, 2 or 3) based on its amino acid sequence. Conservation within the allelic groups ranges from 91.6% -100%, while conservation between these groups is as low as 62% (19, 26) . fH can bind to all three fHBP variants (25) , but bactericidal antibodies induced by fHBP are variant-specific. Variant 1 fHBP is found in approximately 60% of disease-producing serogroup B isolates (44) and is present in the 5CVMB MenB vaccine (10) . fHBP is the principal antigen of another MenB vaccine containing recombinant proteins from two different variant sub families, which is currently in clinical trials (called LP2086) (reviewed in 3, 45). Additional vaccines being investigated have been focused on OMVs isolated from a strain overexpressing variant 1 fHBP (16, 21) as well as on recombinant chimeric fHBP (1).
Some non-bactericidal anti-fHBP antibodies are able to confer passive protection against meningococcal infection in the infant rat animal model, most likely via opsonophagocytosis (OP) (16) or interactions with other components of the immune response. LL-37, a cationic antimicrobial peptide, is a key component of the human innate immune system that is constitutively expressed by leukocytes including monocytes, neutrophils, T cells, NK cells, and B cells, and inducibly expressed by epithelial cells (7) , including the epithelial cells of the nasopharynx (24) . LL-37 is a short, positively charged, α-helical peptide that has a broad spectrum of antimicrobial activity, through its direct targeting and disruption of the negatively charged bacterial surface membrane (31) as well as its immunoregulatory roles (4) . The MtrCDE efflux pump, lipid A modification, the type IV pilin secretion system and the capsule (39, 41) are all involved in protection of 5 N. meningitidis against killing by antimicrobial peptides. Two hypothetical genes of N. meningitidis, NMB0741 and NMB1828, have recently been shown to be upregulated in the presence of antimicrobial peptide (along with 19 other gene that are differentially expressed in the presence of CRAMP) and play a role in cathelicidin resistance (9) .
To better characterize the functional role of fHBP, the survival of four strains of N. meningitidis shown to express different levels of fHBP variant 1 (26) , and their ∆fHBP mutant derivative strains, was investigated in ex vivo human whole blood and serum models of meningococcal bacteremia, as well as in vitro survival assays in the presence of antimicrobial peptides (LL-37 and polymyxin B) and other environmental stresses. The results presented show that the expression on fHBP by N. meningitidis strains is important for survival in human blood and human serum regardless of the level of its expression. We also show that fHBP increases meningococcal survival in the presence of the antimicrobial peptide LL-37, which is most likely mediated by electrostatic interactions between fHBP and LL-37 at the cell surface.
MATERIALS AND METHODS
Bacterial strains and culture conditions. N. meningitidis strains used in this study are described in Table 1 . N. meningitidis strains were routinely grown on GC agar (Difco) or Mueller Hinton (MH) agar (Difco) at 37°C/5% CO 2 overnight. For liquid cultures, overnight growth was used to inoculate GC or MH broth. Escherichia coli strains used for cloning were cultured in Luria-Bertani (LB) broth or on LB agar (Difco). When required, erythromycin and/or chloramphenicol were added to achieve a final concentration of 5 µg/ml. Recombinant DNA techniques. Recombinant DNA techniques were routinely performed as described by Sambrook et al. (37) . Plasmid DNA preparations and purification of DNA fragments from PCR samples and agarose were performed using QIAGEN kits according to the manufacturer's instructions. PCR amplification was carried out in a 50µl reaction consisting of 1x 6 reaction buffer, 1.5mM MgCl 2 , 0.2mM dNTPs, 1 unit of Platinum Taq polymerase (Invitrogen), and 10pmol of each forward and reverse primer, an appropriate amount of chromosomal or plasmid DNA and sterilized deionised water. All restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (NEB; Beverly, MA).
Construction of fHBP knockout N. meningitidis strains. The isogenic MC58 wild type and MC58∆fHBP (previously called MC58∆gna1870) knockout mutant, in which the gna1870 gene was truncated and replaced with an erythromycin antibiotic cassette, have been described previously (26) . The pBS∆gna1870ERM knockout plasmid was used to generate isogenic knockout mutants in BZ83, NZ98/254 and 67/00 as described previously (26) . Complementation of the Western blot analysis. Expression of fHBP in whole cell samples and culture supernatants was performed essentially as described previously (26) . Briefly, strains were grown at 37°C /5% CO 2 in MH broth plus 0.25% glucose from an optical density at 600nm (OD 600 ) of 0.05 to 0.5. Bacterial cells were collected by centrifugation, washed once with PBS, and resuspended in SDS-PAGE loading buffer. Culture supernatant was filtered using a 0.2 µm filter and 1 ml precipitated by the addition of 250 µl of 50% trichloroacetic acid (TCA). The sample was incubated on ice for 2 h, centrifuged for 40 min at 4°C and the pellet washed with 70% ice cold ethanol, and resuspended in PBS. Samples were run on 4-12% polyacrylamide gels and electrotransferred onto nitrocellulose membranes. Ponceau staining was performed to ensure equal loadings of the samples. Western blot analysis was performed according to standard procedures using anti-fHBP polyclonal antibodies at a 1:1,000 dilution (raised in mice against the recombinant fHBP purified protein (rfHBP), as described previously (26)), followed by a 1:5,000 dilution of HPR-labeled anti-mouse IgG (SigmaAldrich).
Ex vivo human whole blood and human serum models of meningococcal bacteremia. Cells were harvested into MH broth containing 0.25% glucose and 0.02mM Cytidine-5'-monophospho-Nacetylneuraminic acid sodium salt (CMP-NANA) to an OD 600 of 0.05 and grown to mid-log phase (OD 600 0.5-0.6) then diluted in MH broth to approximately 10 3 colony forming units (CFU)/ml. The assay was started by the addition of 240µl whole human blood, human serum or heat inactivated human serum (56˚C 30 min) to 10µl of bacterial suspension. Cultures were incubated at 37°C/5%CO 2 with gentle agitation, and at various time points an aliquot of the sample was removed and the number of viable CFU were determined by plating serial dilutions onto MH agar and incubating overnight at 37°C/5% CO 2 . Experiments were performed in triplicate on several occasions. The students' t-test was used to determine the statistical significance of survival of each mutant strain with respect to the isogenic wild type strain, with a p-value <0.05 considered to be significant.
Whole venous blood, collected from healthy individuals (unimmunized against N. meningitidis) and anti-coagulated with heparin (10U/ml), was used for whole blood experiments as described by Ison et al. (18) . For preparation of human serum, whole blood was coagulated at 25˚C
for 30 min, centrifuged at 1,000xg for 10 min at 4˚C and the supernatant retained. /xanthine oxidase (200-400mU)). For osmotic stress assays, 10µl of bacterial suspension was added to 90µl of either NaCl (2-5M) or sucrose (10-30%) solutions. Cultures were incubated at 37°C/5%CO 2 with gentle agitation, and CFU were determined as described above.
In vitro
For some experiments, GC broth with a pH of 5, 6, 7, 8, or 9 or 2% NaCl was used to investigate the influence of pH and %NaCl on LL-37 mediated killing. In some cases, LL-37 was also incubated in PBS with varying concentrations of rfHBP or cell free extract for 15 min prior to the assay as described below.
Growth in the presence of LL-37 was monitored using MC58 wild type, MC58∆fHBP and MC58∆fHBP_C strains inoculated into GC broth to an OD 600 of 0.05. Bacteria were incubated at 37°C/5%CO 2 with or without 1µM LL-37 and growth was followed for 5 h by reading the OD 600 .
Investigation of LL-37 -fHBP interactions: peptidase activity assay. The effect of fHBP on LL-37 was investigated using either rfHBP (26) , or cell free extracts from strains MC58 and
MC58∆fHBP. Cell free extracts of overnight cultures of N. meningitidis were prepared by resuspending the cells in PBS, followed by three cycles of freezing and thawing. Unbroken cells and cell debris were removed by centrifugation at 13,000 rpm for 10 min and the supernatant collected and passed through 0.2µm filters. LL-37 (10 µg) was incubated with rfHBP (10µg) or 10µl of cell free extract in PBS at 37˚C and samples were taken at 1 min, 5 min, 15 min, 1 hr and 15
hr and the reactions were stopped by boiling for 5 min. Samples were analyzed by SDS-PAGE (4-12% Tris-tricine gel) and stained with 0.25% Coomassie brilliant blue.
Far-Western dot blot. 5µl spots containing 1.25 or 2.5µg of BSA, rfHBP or LL-37, or 5µl bacterial suspension in PBS (OD 600 of 1) were applied to a nitrocellulose filter. The filter was air dried for 15 min, blocked in 10% milk powder in PBS-0.05% Tween (PBST) overnight and then was incubated with 4.5µg LL-37 in 8ml PBS for 1 hr at room temperature. The membrane was washed 3 times in PBST, then treated as per a normal Western blot, anti-LL-37 polyclonal antibody (Innovagen) was added at a 1:1,000 dilution, followed by a 1:5,000 dilution of HPR-labeled antirabbit IgG (Sigma-Aldrich).
Size-exclusion gel chromatography. Purified recombinant fHBP (98 µg) (26) was incubated with LL-37 (156 µg (1-10 molar ratio) or 78µg (1:5 molar ratio)) in PBS for 1 h and loaded onto a High-Load Superdex_75_10/300 gel filtration column (GE Healthcare) equilibrated with PBS, and 0.5-mL fractions were eluted at a flow rate of 0.8 mL/min. Fractions were analyzed by Western blot using anti-fHBP and anti-LL-37 polyclonal antibodies as described above.
RESULTS

Analysis of fHBP expression and localization in various Neisseria strains. Four strains of
N. meningitidis shown to express different levels of fHBP variant 1 (26) were used in this study to investigate the role of meningococcal fHBP in response to various components of the human immune system (see Table 1 for strain details). Western blot analysis of whole cell extracts of these strains confirms the different levels of fHBP expression (MC58 and BZ83 (high expressors) > NZ98/254 (intermediate expressor) > 67/00 (low expressor))( Figure 1A ). The culture supernatant of these strains was also investigated, and like MC58 (26) , fHBP is present in the culture supernatant of all strains studied ( Figure 1B) . No fHBP was detected in the whole cell extract or the supernatant for the isogenic ∆fHBP mutant strains. Furthermore, fHBP is once again expressed in the complemented strain MC58∆fHBP_C, in which the gene encoding fHBP is inserted in trans under the control of the P tac promoter, however expression is not fully restored to wild type levels ( Fig   1A, B) . strains) indicating the involvement of leukocytes and OP in bactericidal activity. On the other hand, serum from donor 2 mediated more killing of BZ83 and 67/00 strains than blood, suggesting that antibody-mediated SBA is the predominant mode of killing of these strains by this donor.
The phenotype of MC58∆fHBP in whole blood and serum is reversible when a single copy of the fHBP allele is provided in trans (MC58∆fHBP_C; Figures 2A and 3A) , indicating that this phenotype is specifically mediated by fHBP. The lower fHBP expression seen in the MC58∆fHBP_C strain compared to the wild type strain (Figure 1) is consistent with the finding that the complemented strain is not fully rescued from killing by whole blood or serum. The wild type and ∆fHBP strains all behave in a similar manner when incubated for the duration of the assay in GC broth, indicating that differences in survival are not due to intrinsic growth or survival defects (approximately 3 fold increase in CFU over 120 min; data not shown). The wild type and ∆fHBP strains also behave in a similar manner when incubated in heat-inactivated serum, with no growth or killing seen over 120 min (data not shown). These results indicate that bacterial killing in serum is mediated by complement. This is consistent with the role of fHBP in providing resistance to complement mediated killing by binding the complement inhibitor fH (25) ; there is no binding of fH to fHBP in the ∆fHBP strain, enabling increased killing relative to the wild type strain. These results show that the expression of fHBP by N. meningitidis strains is important for survival in human blood and human serum even in strains with low levels of expression.
fHBP of N. meningitidis is involved in resistance to killing by the antimicrobial peptide LL-37.
The presence of an additional role of fHBP, in protection against the antimicrobial peptide LL-37, was discovered during investigation of survival of wild type and ∆fHBP strains in the presence of various antimicrobial compounds. Antimicrobial peptides are an important part of the human innate immune system, which are constitutively produced by leukocytes, and are also present in epithelial cells of the nasopharynx (24), the primary site of meningococcal colonization and infection. In order to determine whether fHBP is involved in protection against killing by antimicrobial peptides, in vitro survival and growth assays were performed with wild type and ∆fHBP strains in the presence of LL-37, a short cationic alpha-helical peptide. MC58, BZ83, NZ98/254 and 67/00 ∆fHBP strains were sensitive to LL-37 with respect to their wild type parent strain (>1 log 10 less survival than wild type at 120 min, P ≤0.01; Figure 4) . Moreover, the MC58 wild type phenotype is restored in the genetically complemented strain, MC58∆fHBP_C ( Figure 4A) . Killing of N.
meningitidis by LL-37 is dose-dependent, with increasing concentrations of LL-37 between 2-5µM mediating increased killing of the wild type strains, and also causing increased sensitivity of the ∆fHBP strain with respect to its wild type parent strain (data not shown). The N. meningitidis strains NZ98/254 and 67/00 are intrinsically more resistant to LL-37 than MC58 and BZ/83 (3.5 µM and 5µM LL-37 used in killing assays shown in Figure 4AB and 4CD, respectively). For NZ98/254 and 67/00, less than 1 log 10 decrease in CFU was seen over 2 hours in the presence of 3.5µM LL-37 compared to an almost 3 log 10 decrease in CFU seen for MC58 and BZ/83 (data not shown). These results show that also in the case of LL-37-mediated killing, fHBP is involved in protection regardless of the expression level of fHBP.
The ability of MC58, MC58∆fHBP, and MC58∆fHBP_C to grow in the presence of 1 µM LL-37, a concentration that only marginally affects the growth of the MC58 wild type strain (9), was also investigated. All strains exhibited similar growth rates in the absence of peptide (doubling times between 55-60 min), however the growth of MC58∆fHBP was significantly decreased in the presence of LL-37 (110 min doubling time), with respect to the wild type (58 min doubling time) and the complemented (68 min doubling time) strains ( Figure 4E ).
In order to determine whether the ∆fHBP mutation altered the integrity of the bacterial membrane or induced a complex phenotype, leading to non-specific sensitivity to LL-37, we performed several additional stress assays. Survival of MC58 and MC58∆fHBP was investigated in the presence of: (1) Here we show that fHBP of N. meningitidis is important for survival in ex vivo models of bacteremia using normal human blood and serum, regardless of the level of its expression by different strains. Recent findings indicate that unlike fHBP of high expressors, fHBP of low expressors is not required for survival in 'nonimmune' human blood (43) . The differences between the results of these two studies are likely due to donor selection. In comparison to nonimmune blood where wild type strains grow or maintain the initial bacterial counts during the experiment, the assay reported herein uses human blood and serum which mediate some killing of the wild type strain (0.5-1 log 10 decrease in CFU over 2 hr), most likely due to background levels of antibodies to N. meningitidis, or cross-reactive antibodies, within the blood of the donors. Using the same 'nonimmune' donor serum from that study, we were able to replicate the finding that NZ98/254∆fHBP did not have greatly reduced survival relative to the wild type strain (43); data not shown).
The findings from this study indicate the importance of a third mode of action by which anti-15 fHBP antibodies induce a bactericidal response ( Figure 5B) . fH, by controlling the key steps in the complement AP amplification cycle, also dampens activation that has been initiated via the complement CP or the lectin pathway (13, 15) . LL-37 may contribute to the sensitivity of the ∆fHBP strains seen in the ex vivo blood and serum assays described above. Since fHBP binds specifically to human, but not rat or mouse, factor H (38), the fact that nonbactericidal antibodies raised against fHBP can provide passive protection in an infant rat model (16) 
